Headquartered in Irving, Texas, McKesson Corporation (MCK) stands as one of the most influential players in global healthcare distribution. The company moves pharmaceuticals, medical-surgical supplies, and critical healthcare products across a vast network that connects biopharma manufacturers, suppliers, pharmacies, and ultimately patients.
With a market cap of nearly $120.9 billion, it occupies the “large cap” field reserved for companies valued at more than $10 billion. The scale reflects its dominant position in healthcare distribution and its broad operational reach in domestic and international markets.
MCK stock is currently at a 52-week high of $987.37, reached in February. Over the past three months, shares have gained 11.7%, while the Nasdaq Composite ($NASX) has fallen 2.4%, marking a short-term outperformance against the broader index.
The long-term trend is strengthening. Over the past 52 weeks, MCK stock has risen 59% and is up 20.4% year-to-date (YTD). Over the same 52-week period, the Nasdaq advanced 22.2% but declined 2.5% YTD. Over both time horizons, McKesson clearly performed relatively well.
The technical structure supports the narrative. Since February, the stock has been trading above its 50-day moving average of $865.65. It remains above the 200-day moving average of $776.06 since April 2025.
On February 5, MCK stock rose 16.5% after the release of fiscal 2026 Q3 results a day earlier. During the quarter, revenue reached $106.2 billion, matching analyst expectations and marking 11.4% year-over-year growth. Adjusted EPS rose 16.3% to $9.34, beating Street estimates of $9.27.
Growth stemmed from strong oncology performance, expanding biopharma services, and continued momentum in North American drug distribution. Management bolstered that confidence by raising its full-year non-GAAP earnings outlook, suggesting growth of 17% to 19% over last year.
To frame McKesson’s performance in context, competitor Cencora, Inc. (COR) has gained 49.5% over the past 52 weeks and is up 10.2% YTD. While Sencora has delivered impressive returns, McKesson is the leader in both the long-term and YTD measures.
